Biotechnology

Novavax

Novavax Raises 2025 Revenue Forecast

Novavax released FY2026 Q1 earnings on May 6 Pre-Market EST, actual revenue USD 139.51 M (forecast USD 80.99 M), actual EPS USD -0.06 (forecast USD -0.226)

Novavax to Release FY2026 Q1 Earnings on May 6 Pre-Market EST, Forecast Revenue USD 80.99 M, EPS USD -0.226

Novavax released FY2025 Annual Earnings on February 26 Pre-Market (EST), Actual Revenue USD 1.123 B (Forecast USD 1.064 B), Actual EPS USD 2.575 (Forecast USD 2.1498)

Novavax released FY2025 Q4 earnings on February 26 Pre-Market EST, actual revenue USD 147.14 M (forecast USD 89.86 M), actual EPS USD 0.1078 (forecast USD -0.4893)

Novavax Reports Q4 Earnings Above Expectations

Novavax to Release FY2025 Q4 Earnings on February 26, 2026 Pre-Market EST, Forecast Revenue USD 90.26 M, EPS USD -0.4936

Analyst Gives Novavax a Buy Rating with a Target Price of $11

Novavax Signs License and Option Agreement with Pfizer for Matrix-M Technology

FDA Plans to Issue 'Black Box' Warnings for COVID-19 Vaccines

B. Riley Reaffirms Novavax 'Buy' Rating and Cuts Target Price

Novavax released FY2025 Q3 earnings on November 6 Pre-Market (EST), actual revenue USD 70.45M (forecast USD 44.87M), actual EPS USD -1.25 (forecast USD -0.9167)

Novavax released FY2025 9 Months earnings on November 6 Pre-Market (EST), actual revenue USD 976.34 M, actual EPS USD 2.3005

NovaVax Executives Forecast Significant Increase in Royalty Fees for 2026-2027 Flu Season

Novavax Reports Q3 EPS Loss of $1.25

Novavax Raises 2025 Annual Revenue Forecast

Novavax Reports Q3 Revenue Exceeding Wall Street Expectations

Novavax to Report Q3 Earnings on Nov 6

Novavax Transfers Nuvaxovid US Market Authorization to Sanofi

Novavax Receives Multiple Firm Ratings

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

Silexion Therapeutics

GCL Global

MetaVia

MicroAlgo

Vida Global

BiomX

ENPH

ENPX

Enphase Energy Inc. (ENPH) shares fell 6.05% to $49.69 on Monday, ending a three-day winning streak. The stock is 7.80% below its 52-week high of $53.89. In comparison, competitors like Eaton Corp. (ETN), TE Connectivity (TEL), and Amphenol (APH) also saw declines, but less severe. Trading volume reached 11.8 million, surpassing the 50-day average of 6.7 million.

MarketWatch Automated

Enphase Energy

Tradr 2X Long ENPH Daily ETF

Dow Jones Industrial Average

S&P 500

Eaton

TE Connectivity

Amphenol

Enphase Energy Inc. Stock Underperforms Monday When Compared To Competitors

NXTG

SNSR

Motorola Solutions Inc. (MSI) shares fell 1.52% to $393.28 on Friday, underperforming against competitors amid a broader market decline. The S&P 500 dropped 1.24% and the Dow Jones fell 1.07%. MSI's stock is 20.10% below its 52-week high of $492.22. Competitors L3Harris Technologies and Axon saw declines of 1.38% and 0.95%, while Tyler Technologies rose 4.28%. Trading volume reached 1.2 million, surpassing the 50-day average of 1.1 million.

Motorola Solution

First Trust Index NextG ETF

SPDR S&P Software

iShares Expanded Tech Software Sector ETF

Comm Servcies Select Sector SPDR

Global X Internet

L3Harris Tech

Tyler Tech

Axon Enterprise

Factset Research

Motorola Solutions Inc. Stock Underperforms Friday When Compared To Competitors

NVAX

IBBQ

SBIO

ARKG

LABU

Novavax Inc. (NVAX) shares rose 1.30% to $9.35 on a strong trading day, outperforming competitors like Johnson & Johnson (up 0.16%), while Pfizer and Merck saw declines. The NASDAQ Composite Index increased by 0.88% and the Dow Jones by 0.75%. Novavax remains 21.89% below its 52-week high of $11.97 reached on February 26. Trading volume was 4.6 million, surpassing the 50-day average of 4.4 million.

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

NASDAQ Composite Index

Johnson & Johnson

Pfizer

Merck

Novavax Inc. Stock Outperforms Competitors On Strong Trading Day

WKHS

Shares of Workhorse Group Inc. (WKHS) fell 5.00% to $3.42 on Tuesday, underperforming compared to competitors like Tesla Inc. (TSLA) and General Motors Co. (GM). The stock is currently 94.92% below its 52-week high of $67.32. The overall market saw mixed results, with the Dow Jones up 0.11% and NASDAQ down 0.71%. Trading volume was below the 50-day average.

Workhorse

Tesla

General Motors

Workhorse Group Inc. Stock Underperforms Tuesday When Compared To Competitors

BlackRock Inc. (BLK) shares rose 1.03% to $1,092.50 on Tuesday, despite underperforming compared to competitors like JPMorgan Chase, Wells Fargo, and Morgan Stanley. The Dow Jones Industrial Average increased by 0.11%, while the S&P 500 fell by 0.16%. BlackRock's stock remains 10.45% below its 52-week high of $1,219.94, reached on October 15th.

BlackRock

JPMorgan Chase

Wells Fargo

Morgan Stanley

BlackRock Tech and Private Equity Term Trust

BLACKROCK MULTI-SECTOR INCOME TR COM USD0.001(S/R 09/09/2025) WI

Blackrock Enhanced Div Achievers Trust

BlackRock Science and Tech Term Trust

BlackRock Multi-Sector Income Trust

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

BlackRock Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

MRNA

Moderna's (MRNA) stock rose about 9% in pre-market trading, building on a 12% gain from Friday, following a confirmed Hantavirus case in a U.S. traveler. The outbreak on the MV Hondius cruise ship has resulted in three deaths and at least six infections. Moderna is conducting early vaccine research for Hantavirus, although it is still in preliminary stages. Analysts rate MRNA as a Hold, with one Buy, 12 Holds, and one Sell, and an average price target of $44.71, indicating an 18% potential upside.

Tip Ranks

Moderna

Moderna Stock (MRNA) Extends Breakout amid Hantavirus Fears

Novavax Stock Is Red Hot but the Smart Money Is Slamming on the Brakes

Barchart Option

iShares Global Healthcare

Health Care Select Sector SPDR

VG Health

Novavax Stock Is Red Hot but the Smart Money Is Slamming on the Brakes

Novavax Inc. (NASDAQ: NVAX) shares are seeing increased trading activity following Moderna Inc.'s (NASDAQ: MRNA) announcement of early-stage research on hantavirus vaccines. Despite recent cruise ship deaths linked to a virus, health experts deem the risk to public health minimal. Moderna is collaborating with the U.S. Army Medical Research Institute on this vaccine development. Meanwhile, Pfizer and BioNTech have paused their COVID vaccine trial due to low enrollment.

Novavax(NVAX.US)

Enphase Energy Inc. Stock Underperforms Monday When Compared To Competitors

Motorola Solutions Inc. Stock Underperforms Friday When Compared To Competitors

Novavax Inc. Stock Outperforms Competitors On Strong Trading Day

Workhorse Group Inc. Stock Underperforms Tuesday When Compared To Competitors

BlackRock Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

Moderna Stock (MRNA) Extends Breakout amid Hantavirus Fears

Novavax Stock Is Red Hot but the Smart Money Is Slamming on the Brakes

What's Going On With Novavax Stock On Friday?